BioHarvest Sciences (BHST) Q2 2026 Earnings Call Transcript

BioHarvest Sciences reported Q2 2026 revenue of $8.8M (+3.8% YoY) and an improved net loss of $3.7M ($0.17/share) vs. $4.1M ($0.24/share) a year ago, with cash rising to $16.2M from $3.7M. Management secured a first rare-fragrance CDMO supply/manufacturing agreement with a 20-ton commitment, projecting $20M–$30M of potential 2027–2028 revenue, but revised FY2026 consolidated revenue guidance down to $37M–$40M (from $42M–$48M) due to strategic resource reallocation. Consolidated EBITDA loss guidance remained large at $3M–$5M (vs. prior $3M–$4M), while CDMO revenue was tightened to $4M–$5M and CDMO EBITDA loss reduced to $1.5M–$2.5M.

Analysis

Near term, the stock should trade as a capital-allocation story, not a commercialization story: the headline contract does not create cash today, and the implied 2027 monetization is too far out to offset a 2026 guide reset. The important mechanism is that management is swapping low-visibility D2C spend for higher-ROIC capacity and CDMO work, which lowers dilution risk but also delays top-line acceleration. That usually compresses the multiple first, then only re-rates if the next two quarters show real conversion from development to manufacturing revenue.

The second-order winners are the ingredient/platform partners, not the consumer brand itself. If this model works, larger buyers like Tate & Lyle/Ingredion can use BioHarvest as an IP and process layer while pushing volume into their own facilities later, which is better economics for them than funding speculative in-house biology. The loser in the interim is the standalone D2C narrative: higher media inflation means marginal CAC is rising faster than lifetime value, so VINIA needs proof that pricing and new formats are lifting retention rather than merely defending revenue.

Contrarian takeaway: the market may overreact to the revenue cut and underappreciate the balance-sheet improvement, but it may still underprice execution risk on the CDMO ramp. The bull case is falsified if customer growth stalls after the price increase, if gross margin slips below the high-50s, or if capex working capital creeps high enough to force an equity raise before the 2027 breakeven target. The next 1-3 months matter for sentiment; the 6-18 month window is where the franchise either becomes licensable infrastructure or remains a story stock.

Key Decisions for Investors

• Short BHST on post-earnings strength or via a 1-3 month put spread; thesis is that the guide cut and delayed revenue recognition outweigh the contract headline, with downside tied to multiple compression rather than immediate earnings misses.
• Do not buy BHST for the 2027 contract until management discloses royalty economics and first-half 2027 production milestones; if 2H26 CDMO bookings do not inflect, the current valuation has little fundamental support.
• Use BHST as a watchlist name for a tactical long only if Q4 shows stable active customers, no dilution, and improved conversion after the September product launch; otherwise treat it as an avoid, not a buy.
• Watch TATYY as a secondary beneficiary of the licensing/technology-transfer model, but only consider a small long after evidence that BioHarvest’s sweetener collaboration converts into a real manufacturing or royalty framework.
• Set an alert if BHST cash drops toward the low-$10mm range or if capex guidance re-accelerates; either would likely force financing and invalidate the current balance-sheet discipline thesis.